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Abstract
We investigated the mechanism(s) of action of two new putative antiepileptic drugs (AEDs), (S)-(-)-10-acetoxy-10,11-dihydro-5H-
dibenz[b,f]azepine-5-carboxamide (BIA 2-093) and 10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-5-carboxamide (BIA 2-024),
by comparing their effects on the release of endogenous glutamate in hippocampal synaptosomes, with those of carbamazepine (CBZ) and
oxcarbazepine (OXC). The AEDs inhibited the release of glutamate evoked by 4-aminopyridine (4-AP) or veratridine in a concentration-
dependent manner, being CBZ more potent than the other AEDs. Using conditions of stimulation (30 mM KCl), where Na1 channels are
inactivated, the AEDs did not inhibit either the Ca21-dependent or -independent release of glutamate. The results indicate that BIA 2-093
and BIA 2-024 have sodium channel-blocking properties, but CBZ and OXC are more potent than the new AEDs. Moreover, the present
data also indicate that Ca21 channels coupled to the exocytotic release of glutamate and the activity of the glutamate transporter were not
affected by the AEDs. © 2001 Elsevier Science Inc. All rights reserved.
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1. Introduction
During the last decade several new AEDs have been
developed to treat epilepsy, such as OXC, which is an
analogue of CBZ, and is generally accepted as a better
tolerated drug [1]. (S)-(2)-10-acetoxy-10,11-dihydro-5H-
dibenz[b,f]azepine-5-carboxamide (BIA 2-093) [2] and
10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-
5-carboxamide (BIA 2-024) [3] are new putative
AEDs, chemically related to CBZ and OXC, but specifi-
cally designed to prevent the production of toxic metabo-
lites.
The mechanisms underlying the effects of the AEDs
are still a matter of debate. It has been shown that CBZ
and OXC inhibit voltage-sensitive sodium [4,5] and cal-
cium currents [6,7], and that BIA 2-093 has sodium
channel-blocking properties [2]. We recently found that
CBZ inhibits L-type Ca21 channels in hippocampal neu-
rons [8].
Focal application of glutamate to the surface of the
cerebral cortex evokes local epileptiform activity. Thus,
inhibition of glutamate release may contribute to the
efficacy of anticonvulsants against epileptic seizures. In
the present work, we investigated the effects of the an-
ticonvulsants on the release of endogenous glutamate
from hippocampal nerve terminals, particularly their pos-
sible interaction with the Na1 and Ca21 channels present
in nerve terminals, namely P/Q-type channels, which
have a predominant role on the exocytotic release of
glutamate [9].
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2. Materials and methods
2.1. Preparation of synaptosomes
A partially purified synaptosomal fraction (P2) was iso-
lated from the hippocampi of male Wistar rats (2 months of
age) as described previously [9].
2.2. Endogenous glutamate release experiments
The release of endogenous glutamate was followed by
using a continuous fluorimetric assay, as previously de-
scribed [10]. The synaptosomes (1 mg) were incubated for
30 min at 37°C in the following medium (in mM): 132
NaCl, 1 KCl, 1 MgCl2, 1.2 H3PO4, 0.1 CaCl2, 10 glucose,
10 HEPES-Na, at pH 7.4, with 0.1% fatty acid-free bovine
serum albumin (BSA), centrifuged, and then resuspended in
1 ml of the same medium with 1 mM NADP, 50 U of
purified L-glutamic acid dehydrogenase type II (EC 1.4.1.3;
Sigma), 1 mM CaCl2 or with 200 nM free Ca21 (without
BSA).
Fluorescence was measured by using a luminescence
spectrometer (Perkin Elmer model LS-5B) at excitation and
emission wavelengths of 340 nm and 460 nm, respectively,
with excitation and emission slits of 5 nm and 10 nm,
respectively. The data were collected at 0.5 s intervals and
the quantitation of glutamate release was performed at the
end of each experiment by adding 2.5 nmol of L-glutamate.
2.3. Chemicals and data analysis
Carbamazepine, oxcarbazepine, BIA 2-093 and BIA
2-024 were obtained from BIAL, S. Mamede do Coronado,
Portugal. Veratridine, 4-AP, tetrodotoxin, NADP and L-
glutamic acid dehydrogenase type II (EC 1.4.1.3) were
purchased from Sigma Chemical Co. All other reagents
were from Sigma or from Merck-Schuchardt, Germany.
CBZ, OXC, BIA 2-093, BIA 2-024 and veratridine stock
solutions were prepared in DMSO.
The data are expressed as means 6 SEM. Statistical
significance was determined by using an analysis of vari-
ance (ANOVA), followed by Dunnett’s post-test. The
dose-inhibition curves for the effects of CBZ, OXC, BIA
2-093 and BIA 2-024 represent the best fit according to
nonlinear regression analysis (one site competition), as-
suming bottom and top values of 0% and 100%, respec-
tively.
3. Results and discussion
Stimulation of hippocampal synaptosomes with 100 mM
4-AP evoked the release of 4.6 6 0.1 nmol glutamate/mg
protein/5 min, and the AEDs inhibited the release of gluta-
mate, as illustrated in Fig. 1, in a concentration-dependent
manner (Fig. 2). Carbamazepine was more potent than
OXC, BIA 2-093 or BIA 2-024. The IC50 values for CBZ,
OXC, BIA 2-093 or BIA 2-024 were 99.3 6 1.08 mM,
156.8 6 1.23 mM, 233.0 6 1.14 mM or 188.0 6 1.13 mM,
respectively.
Veratridine (5 mM) evoked the release of 6.6 6 0.2
nmol glutamate/mg protein/5 min. Again, the AEDs in-
hibited the release of glutamate in a concentration-depen-
dent manner (Fig. 3), and CBZ was again more potent
than OXC, BIA 2-093 or BIA 2-024. The IC50 values for
CBZ, OXC, BIA 2-093 or BIA 2-024 were 123.9 6 1.07
mM, 156.9 6 1.15 mM, 232.3 6 1.07 mM or 190.8 6
1.11 mM, respectively.
When synaptosomes were stimulated with 30 mM KCl
the release of glutamate was 6.8 6 0.5 nmol glutamate/mg
protein/5 min. The Ca21-independent glutamate release was
36.7 6 2.9% of total release (data not shown). Moreover, 1
mM tetrodotoxin did not inhibit the release of glutamate
evoked by 30 mM KCl (data not shown), indicating that
voltage-sensitive sodium channels are inactivated. The
AEDs (300 mM) did not inhibit the KCl-evoked (exocytotic
plus non-exocytotic) glutamate release (data not shown).
Also, the AEDs did not inhibit the non-exocytotic KCl-
evoked glutamate release (200 nM external Ca21, data not
shown).
In the present study, we investigated the effects of
BIA 2-093, BIA 2-024, CBZ and OXC on the exocytotic
and/or carrier-mediated release of endogenous glutamate
in hippocampal nerve terminals. As shown previously,
P/Q-type Ca21 channels have a predominant role on the
exocytotic release of endogenous glutamate [9]. Because
CBZ [6,8] and OXC [7] inhibit calcium channels, we
investigated whether the AEDs could inhibit P/Q-type
calcium channels present in nerve terminals. The inhib-
itory effect caused by the AEDs on the release of gluta-
mate evoked by 4-AP or veratridine could be due either
to the inhibition of sodium channels, to the inhibition of
calcium channels coupled to the exocytotic release of
glutamate, or in part due to the inhibition of the glutamate
transporter. However, the AEDs did not inhibit the re-
lease of glutamate when sodium channels are inactivated
Fig. 1. Illustrative recordings of endogenous glutamate release stimulated
by 100 mM 4-AP in hippocampal synaptosomes (1 mM Ca21 present in the
external medium). Synaptosomes were stimulated for 5 min with 4-AP, and
the AEDs were present since the beginning of the experiment. (A) Control
(B) Effect of 300 mM CBZ.
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(stimulation with 30 mM KCl), indicating that the inhi-
bition caused by the AEDs on the 4-AP- or veratridine-
evoked glutamate release was due to the inhibition of
sodium channels and not to the inhibition of calcium
channels or the glutamate transporter.
It was previously shown that CBZ and OXC inhibit the
release of glutamate elicited by veratrine or veratridine
[11,12], however it is uncertain whether these effects are
relevant in vivo at anticonvulsant doses. It was also
reported that CBZ inhibits glutamate release by prefer-
entially blocking sodium channels [13]. In the present
work, the release of glutamate stimulated by 4-AP or
veratridine was significantly inhibited by CBZ at concen-
trations similar to those found in plasma levels (17–51
mM) [14]. Since OXC, BIA 2-093 and BIA 2-024 signif-
icantly inhibited the release of glutamate at higher con-
centrations, it is not clear whether these effects are rel-
evant in vivo.
In conclusion, our results show that BIA 2-093 and BIA
2-024 have antagonistic properties on sodium channels,
however with lower potency when compared to CBZ or
OXC. The AEDs tested neither affected the calcium chan-
nels, which are coupled to the exocytotic release of gluta-
mate, nor the glutamate transporter.
Fig. 2. Dose-inhibition curves for the effect of CBZ, OXC, BIA 2-093 or BIA 2-024 on the release of endogenous glutamate evoked by 100 mM 4-AP (1
mM Ca21 present in the external medium). The results represent the mean 6 s.e.m. of three to eight independent experiments, in different synaptosomal
preparations, and are presented as percentage of control. *P , 0.05; **P , 0.01-Dunnett’s post-test; Statistical significance when compared to control
(4-AP stimulation).
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